secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001193125-23-141380
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera Therapeutics Q1 net loss $17.7M; avasopasem NDA gets FDA priority review with PDUFA Aug 9
--------------------------------------------------------------------------------

- Net loss of $17.7M ($0.50 per share) in Q1 2023 vs $15.4M ($0.58 per share) in Q1 2022.
- Cash, cash equivalents and short-term investments of $47.8M as of March 31, 2023; expected to fund operations into Q4 2023.
- FDA granted priority review for avasopasem NDA for radiotherapy-induced severe oral mucositis; PDUFA date August 9, 2023.
- Raised $30M gross proceeds from registered direct offering in February 2023.
- Expanded commercial leadership team with three new VPs in preparation for potential U.S. launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312523141380/0001193125-23-141380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312523141380/d476140d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-141380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer